GUTS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 5.21%, SMA50 -67.18%, SMA200 -67.99%). The stock’s 14-day RSI is 27.15 (weak momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.33% below its high and over 25.85% above its low. Average 10-day trading volume of 2.02 million shares is slightly above the 3-month average of 1.68 million, indicating heightened recent market interest.

Fractyl Health, Inc. has 70.88 million shares outstanding. The public float is 27.94 million shares, elevated short interest at 8.20% of float. This equals 2.00 million shares. The short ratio is 8.02 days. Institutional investors hold 53.12% of the float. Insiders own 1.35%. CVF, LLC holds 4.67 million shares, Rajagopalan Harith has 540.56 thousand shares and BRADLEY WILLIAM has 84.62 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Fractyl Health, Inc. generated EPS of -$2.27 over the past year. Five-year average earnings growth is -12.32%. Wall Street analysts project EPS growth of 26.37% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $2.00. The high target offers 1185.71% upside. The low target suggests 185.71% downside. The mean target is $7.00. This offers 900.0% upside. Fractyl Health, Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by -11.11%. The prior quarter beat by -135.29%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 13, 2025.

Fractyl Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

Fractyl Health, Inc. (NASDAQ:GUTS) closed at $0.70 USD, gaining $0.01 (1.35%) from the previous close of $0.69. The stock is currently mid-range between its 52-week high and low $0.38 and $2.44. With a market capitalization of about $110.51 million, Fractyl Health, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.32). Key stats such as the average daily volume over the past year has been around 1.70 million shares, volume is running light vs its 52-week average. Headquartered in Burlington, MA, Fractyl Health, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Harith Rajagopalan, the company employs approximately 100 people and listed since February 02, 2024. Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

Fractyl Health, Inc. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -66.3 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.34, also above market averages.

Our AI price prediction model suggests that Fractyl Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.92%, with price expected at $0.71 by September 17, 2026, within a range of $0.67 to $0.75 3-Month Outlook: Projected rise of 93.8%, reaching $1.35 by December 02, 2026, with a range of $1.22 to $1.46. 1-Year Outlook: Projected gain of 370.86%, with price at $3.28 by September 03, 2027, within a range of $0.08 to $3.19.

Fractyl Health, Inc. (NASDAQ:GUTS) shares are down -13.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Fractyl Health, Inc. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.88, suggesting 887.65% upside. Our AI forecast model points to short-term strength (1.92% over two weeks), a medium-term rise (93.8% over three months), and a longer-term gain (370.86% over one year), with expected trading ranges indicating moderate volatility.